Different concentrations of nivolumab reduce PD-1 expression but not tumour growth in an EMT6 mouse model
Introduction: The interaction between the T cell immune checkpoint proteins, the programmed death-1 (PD-1) receptor, and its ligand PD-L1 plays a crucial role in T cell suppression and the evasion of cancer cells from immune detection, thereby promoting tumour growth. Nivolumab, a PD-1 inhibitor, di...
发表在: | Biomedical Research and Therapy |
---|---|
主要作者: | |
格式: | 文件 |
语言: | English |
出版: |
BiomedPress
2024
|
在线阅读: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85219117249&doi=10.15419%2fbmrat.v11i2.864&partnerID=40&md5=97a6ca65123b9e18dce0e02386748aa6 |